research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
Ritlecitinib is generally safe for alopecia areata patients over 72 months.
Search
for
Sort by
Research
300-330 / 1000+ results research Polymer conjugated retinoids for controlled transdermal delivery
A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with less inflammation.
research New treatments for rheumatoid arthritis
New drugs for rheumatoid arthritis show improvement but have side effects and are not a cure.
research Recent discoveries and developments of androgen receptor based therapy for prostate cancer
New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.
research Alopecia side-effect of antituberculosis drugs
Some tuberculosis drugs may cause hair loss, but hair might regrow after treatment or changing the drugs.
research Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
research Acute Encephalomyelitis Syndromes Associated with H1N1 Influenza Vaccinations; Erythema Multiforme Secondary to H1N1 Vaccine; Cytolytic Hepatitis Possibly Related to Oral Contraceptives; Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Associated with Lamotrigine: First Report; Behavioral Disinhibition with Baclofen; Minoxidil-Induced Trichostasis Spinulosa of Terminal Hair; Delayed-Onset Mirtazapine-Related Leukopenia
Various medications and vaccines can cause serious side effects.
research ALOPESIA AREATA DENGAN TERAPI KOMBINASI INJEKSI PLATELET-RICH PLASMA (PRP) DAN TRIAMSINOLON ASETONID INTRALESI
The combination of PRP and triamcinolone injections improved hair growth in a man with alopecia areata.
research Tu1491 – Use of Androgen Lowering Medications Finasteride and Dutasteride Do Not Substantially Alter Risk of Incident Hcvrelated Hepatcellular Carcinoma in Men
Androgen lowering medications don't significantly change HCV-related liver cancer risk in men.
research 5-Alpha Reductase Inhibitor Use and Prostate Cancer Prevention: A Victim of the Times?
5-Alpha reductase inhibitors are safe long-term but may be outdated for preventing less significant prostate cancer.
research Table of Contents
Second-generation antipsychotics offer no significant benefit over first-generation ones for schizophrenia.
research HDL as Therapeutic Tools
Modified HDL can better deliver drugs and genes, potentially improving treatments and reducing side effects.
research TOPICAL PHARMACEUTICAL COMPOSITIONS
The composition helps treat hair loss.
research Therapeutics for COVID-19 and post COVID-19 complications: An update
New treatments for COVID-19 show promise, but more effective antiviral drugs are needed.
research The role of retinoids in the management of cutaneous conditions in blacks
Retinoids help manage skin conditions in black individuals.
research Cutaneous Manifestations of the Acquired Immunodeficiency Syndrome Update 1987
AIDS patients often have specific skin conditions that help in early diagnosis and management.
research The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells
The drug enzalutamide may reduce the ability of the virus causing COVID-19 to enter lung cells.
research European expert consensus statement on the systemic treatment of alopecia areata
Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.
research Risk of rhabdomyolysis from 5-α reductase inhibitors
Starting 5-alpha reductase inhibitors does not significantly increase the risk of rhabdomyolysis in older men, but is linked to a higher risk of muscle conditions.
research What’s Sex Got to Do With COVID-19? Gender-Based Differences in the Host Immune Response to Coronaviruses
Men generally have more severe COVID-19 cases and higher death rates than women due to biological differences.
research Applications of platelet-rich plasma in dermatology: A critical appraisal of the literature
Platelet-rich plasma may have some benefits in dermatology, but there's not enough evidence to widely recommend its use.
research Hair follicles as a target structure for nanoparticles
Nanoparticles around 600-700 nm can effectively enter and stay in hair follicles for days, which may help in delivering drugs to specific cells.
research Semecarpus anacardium Linn.: A review
Semecarpus anacardium Linn. has many medicinal benefits.
research Clinical perspectives on the age-related increase of immunosuppressive activity
Aging and chronic inflammation weaken the immune system, increasing cancer and infection risks.
research Exploring the Drug Repurposing Versatility of Valproic Acid as a Multifunctional Regulator of Innate and Adaptive Immune Cells
Valproic Acid could potentially be used to treat immune-related conditions due to its ability to modify immune cell functions.
research Hair and Scalp Manifestations in Secondary Syphilis: Epidemiology, Clinical Features and Trichoscopy
Hair loss in secondary syphilis is more common than thought and can be reversed with antibiotics.
research Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome
Obese women with PCOS are more likely to have fatty liver disease.
research Fat, Stem Cells, and Platelet-Rich Plasma
The conclusion is that fat grafting is safe and effective but carries risks that need careful management.
research Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures
A blood pressure drug, diltiazem, may also help treat influenza.
research Follow‐up of Adverse Drug Reactions from Peginterferon alfa‐2b—Ribavirin Therapy
Peginterferon alfa-2b and ribavirin therapy for hepatitis C can cause serious side effects, some different from those reported in clinical trials.